The Role of Metabolism in the Estrogenic Activity of Endocrine-Disrupting Chemicals

Exposure to several natural and synthetic chemicals can disrupt the endocrine system and thus present a threat to human health. In vivo , such chemicals can be metabolized, which can change the endocrine activity of the parent chemical. Metabolism is usually considered to be a detoxification process, as it generally appears to reduce the estrogenic activity of a chemical and accelerate its elimination from the body. This is seen for bisphenol A (BPA), a known agonist of the estrogen receptor, whereby BPA glucuronide has no effects on this receptor. In contrast, numerous metabolites that show significantly greater estrogenic activities from their parent chemicals have been described in the literature. An example is the ipso metabolite of BPA, 4-methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene, which shows >100-fold estrogenic activity compared to BPA. Consideration of metabolic pathways in in vitro models is therefore of great importance for reliable analysis and correct in vitro to in vivo correlations. The inclusion of metabolic aspects in these assays will reduce false-positive data for chemicals that are detoxified in vivo and false-negative data for proestrogens. Different approaches for this incorporation of metabolic systems for determination of estrogenic activities are already in use and are described in the present chapter. An estrogenic substance is released from polycarbonate flasks during autoclaving.


Introduction
According to the World Health Organization definition from 2002, an endocrine-disrupting chemical (EDC) is an exogenous substance, or a mixture of substances, that alters the function(s) of the endocrine system and consequently that causes adverse health effects in the intact organism or its progeny or in (sub) populations [1]. The occurrence of EDCs in the environment is widespread, and exposure to EDCs is connected with many modern illnesses, such as cancers and metabolic syndrome [2,3]. Effects of some EDCs on nuclear receptors have been reported even at very low doses, and thus EDCs have promoted increased concern among scientists and regulators [4][5][6]. As a result, over the last two decades, numerous in vitro and in vivo assays have been developed for the identification of EDCs [7,8]. In vitro assays represent an important step, especially in the early stages of testing, as they can provide valuable information about the mechanisms of endocrine disruption (e.g., binding to the estrogen receptor [ER]). The main drawback of commonly used in vitro systems for estrogenic activity is that they do not consider pharmacokinetic parameters and especially the metabolism of a tested chemical [9].
Metabolism is the enzymatic process by which lipophilic compounds are transformed into hydrophilic metabolites, which can then be rapidly excreted with the urine. The liver is the main site of drug metabolism, although metabolic reactions also occur in extrahepatic tissues, like the gut and the airways [10]. Phase I metabolic reactions mainly consist of oxidation, reduction, and hydrolysis. During phase I metabolism, new polar functional groups, like hydroxyl or carboxyl groups, are introduced into the parent molecules, which results in either excretion of the modified chemical with the urine or in further metabolism by phase II metabolic reactions. During phase II metabolism (i.e., conjugation reactions), chemicals are conjugated with endogenous hydrophilic molecules (e.g., glucuronic acid, sulfate, glycine, and acetyl group), which strongly increases their hydrophilicity and facilitates their excretion. Metabolism can also influence the biological activity of a chemical. In most cases, metabolism works as a detoxification system, as it can convert biologically active chemicals into less active or even inactive metabolites [11]. In contrast, some chemicals that have no initial biological activity can be metabolically activated to a biologically active chemical (i.e., prodrugs) [12]. The principle of prodrugs is often used in the pharmaceutical industry, with the aim being to improve the pharmacokinetics of drugs [13]. For example, enalapril is a medication that is used for the treatment of arterial hypertension, and in the body, it is metabolized by esterases to the pharmacologically active compound enalaprilat [14]. Additionally, some chemicals can be metabolized to reactive metabolites, as seen for the thiophene moiety [12], and can have detrimental effects.
Thus, metabolism can strongly influence the endocrine activities of many chemicals. Rybacka and coworkers developed an in silico model for the prediction of endocrine-disrupting potential of industrial chemicals and their metabolites [15]. More than 6000 industrial chemicals were evaluated using this model, and 9% of them were predicted to be positive for interactions with the ER. However, when metabolism was incorporated into this model, this doubled the number of chemicals that were defined as positive for interactions with the ER [15]. Metabolism can, for example, significantly affect antiestrogenic and antiandrogenic activities of the new Figure 1. Metabolism of the new brominated flame retardants TBB and TBPH to their TBBA and TBMEPH metabolites that show antiestrogenic and antiandrogenic activities, as determined using a yeast assay [16]. ER, estrogen receptor; AR, androgen receptor. brominated flame retardants 2-ethylhexyl 2,3,4,5-tetrabromobenzoate (TBB) and bis(2-ethylhexyl) tetrabromophthalate (TBPH). While these parent chemicals show no activity toward ERs and androgen receptors, their metabolites 2,3,4,5-tetrabromobenzoic acid (TBBA) and 2-ethylhexyltetrabromobenzoate ester (TBMEPH) show antiestrogenic and antiandrogenic activities with IC 50 values in the low micromolar ( Figure 1) [16].
However, as in vitro assays do not generally consider metabolic transformations of chemicals, it can be difficult to detect chemicals without estrogenic activities that are converted to metabolites with estrogenic activities (i.e., proestrogens). Moreover, in vitro estrogenic activities can be overestimated for compounds that are metabolized to inactive metabolites in vivo [17]. This can result in poor in vitro to in vivo predictions, as observed with benzyl-butyl phthalate, which has estrogenic activity in the T47D-KBluc in vitro assay, but not in the in vivo uterotrophic assay. This can be explained by the rapid hydrolysis of benzyl-butyl phthalate to its monoester in vivo, which has no estrogenic activity [9]. In contrast, methoxychlor metabolites have higher estrogenic activity than methoxychlor itself, which is why the in vivo estrogenic activity for methoxychlor is higher than that predicted from in vitro assays ( Figure 2) [9].

Metabolism of 17β-estradiol
17β-Estradiol (E2) metabolism has been extensively studied, especially in connection with risk of premenopausal breast cancer [18,19]. E2 can undergo aromatic hydroxylation that is catalyzed by cytochromes P450, for the C2 and C4 positions of the steroid rings, to form catechol structures, or for the C16 position of the steroid rings, to form 16-hydroxyestrone structures [20]. Estrogen metabolites with a catechol structure are further metabolized by catechol-O-methyltransferase to their methylated metabolites, as shown in Figure 3. The 16-hydroxyestrones are further metabolized to 17-epiestriols and estriols ( Figure 3). As determined in the urine of premenopausal women, in vivo the 16-hydroxylation pathway of estradiol metabolism is the most important, followed by the 2-hydroxylation pathway, while the 4-hydroxylation pathway represents only minor metabolic conversion [20].
Different environmental factors and polymorphic variations in the genes that encode metabolic enzymes have also been reported to affect estradiol metabolism [24]. Smoking and high physical activity, for example, both favor the 2-hydroxylation metabolic pathway, with the 16-hydroxylation pathway decreased [25,26]. Moreover, Gu and coworkers reported on connections between smoking and increased metabolism of estradiol, increased activity of the 4-hydroxylation metabolic pathway, and decreased methylation of estrogen metabolites [25].
The catechol estrogens 2-hydroxyestradiol and 4-hydroxyestradiol can bind to the ER of MCF-7 cells, and their relative binding activities compared to E2 were reported to be 23 and 26%, respectively [27]. These work as agonists of ERdependent gene expression in the MCF-7 cell line [28].

Impact of metabolism on estrogenic activity
As mentioned above, metabolites with altered estrogenic activity can be formed during metabolism. In some cases, estrogenic activities can be predicted from the structures of the metabolites. Some structural characteristics of the molecule are known to be important for binding to the ER, such as the aromatic ring with an OH group at the para position [30]. Hydroxylation of the para position of the aromatic ring, which is a common phase I metabolic reaction, often enhances estrogenicity. In contrast, glucuronides are devoid of estrogenic activity.

Metabolic activation of proestrogens
A number of chemicals that have been reported to be without estrogenic activities in vitro can affect the estrogen system in vivo. Methoxychlor is a broadspectrum pesticide, and as such it is one of the most studied proestrogens. While methoxychlor has no estrogenic activity, its mono-demethylated and bis-demethylated metabolites have significant estrogenic activities [31]. Mollergues et al. determined the estrogenic activity of methoxychlor using the ER-CALUX assay with and without the β-naphthoflavone-/phenobarbital-induced S9 fraction [32]. In this assay, methoxychlor showed weak estrogenic activity (EC 50 4.6 μM). This estrogenic activity was significantly increased when the activated S9 fraction was added to the assay (EC 50 0.15 μM), which suggested the formation of active metabolites of methoxychlor. The pure methoxychlor metabolite 4,4 0 -(2,2,2trichloroethane-1,1-diyl) diphenol was also tested, and its estrogenic activity was comparable with that of methoxychlor treated with the S9 fraction (EC 50 0.05 μM), which suggested that 4,4 0 -(2,2,2-trichloroethane-1,1-diyl) diphenol is the main metabolite formed with the S9 fraction [32]. As the methoxychlor metabolites mono-OH methoxychlor and bis-OH-methoxychlor are formed both in vitro and in vivo, addition of the metabolic enzymes here (i.e., the S9 fraction) improved the in vivo prediction [33]. Additionally, Sumida and coworkers added a source of metabolic enzymes (i.e., human and rat S9 and liver microsomes) to MCF-7 and Hela reporter gene assays to determine the influence of metabolism on the estrogenic activity of trans-stilbene and methoxychlor [33]. While these parent compounds were without estrogenic activities, the addition of the metabolic enzymes resulted in significant increases in estrogenicity [33].
Permethrin and bifenthrin are pyrethroid pesticides [36]. In in vitro reporter gene assays using the BG-1 cell line (i.e., CALUX bioassays), neither of them showed ER agonist activity, while bifenthrin acted as an ER antagonist. However, both of these pesticides induced expression of chloriogenin (i.e., an E2-responsive protein) in in vivo assays in the juvenile fish Menidia beryllina, which indicated estrogenic activities for both of the parent pesticides or their metabolites in vivo [36]. These differences between the in vitro and in vivo data for permethrin might be due to the formation of metabolites with higher estrogenic activities [37,38]. Similarly, a higher estrogenic activity of the parent bifenthrin that was shown in an in vivo study was also seen for the bifenthrin metabolites [39].

Metabolic inactivation
Inconsistencies in the estrogenic activities obtained in vitro and in vivo were also seen for different phthalates [40]. Here, the tested phthalates (i.e., n-butyl benzyl phthalate, dicyclohexyl phthalate, 2-ethylhexyl phthalate, di-n-butyl phthalate) showed estrogenic activities in an in vitro MCF-7 proliferation assay (i.e., the E-screen assay), but they did not induce expression of calbindin-D 9K mRNA in vivo in neonatal rat uterus [40]. The explanation here might lie in the rapid in vivo metabolism of phthalates to monoester metabolites, which have no estrogenic activity [41]. n-Butyl benzyl phthalate is rapidly metabolized to mono-n-butyl phthalate, mono-benzyl phthalate, hippuric acid, phthalic acid, and benzoic acid [42]. In two in vitro assays (i.e., E-screen assay, progesterone receptor assay on MCF-7 cell line), n-butyl benzyl phthalate showed estrogenic activities, while its metabolites were without activity ( Figure 4) [42].
Loss of estrogenic activity has also been described for various glucuronides. For example, the soy isoflavones genistein and daidzein are known as estrogens [43]. In contrast, their glucuronides are not estrogenic [44]. Despite this, glucuronides have shown very low estrogenic activities in in vitro reporter gene assays using U2OS cells (0.002-0.0005-fold that of their aglycones), which can be explained by their intracellular deconjugation to their corresponding aglycones [44]. Beekmann and coworkers used a cell-free microarray assay for real-time co-regulator-nuclear receptor interactions, which enabled the detection of estrogenicity as an agonistic response to the ER ligand-binding domain (LBD) [45]. They reported 0.125-fold to 0.00022-fold potencies for the glucuronides in comparison with their corresponding aglycones for the modulation of ERα-LBD and ERβ-LBD-coregulator interactions [45].
Similarly, in vitro estrogenic activities were shown for p-nonylphenol and poctylphenol with yeast cells, with EC 50 values in the high nanomolar range (EC 50 110, 700 nM, respectively) [46]. Their glucuronides were without agonistic and antagonistic estrogenic and androgenic activities [46]. Due to the rapid glucuronidation of p-nonylphenol and p-octylphenol in vivo, these in vitro estrogenicities probably do not reflect any hazards in vivo [46].

Bisphenols
The bisphenols are chemicals that contain two phenol rings that are connected through a bridging atom, which can be a carbon or a sulfur, as for BPA and bisphenol S (BPS; bis(4-hydroxyphenyl)sulfone), respectively [47]. BPA is the best known bisphenol as it is used as a monomer in the production of polycarbonate plastic and epoxy resins, and it is also known to be an endocrine disruptor [16, [48][49][50][51][52][53][54]. Both the metabolism and endocrine effects of BPA have been studied in detail, although there remains a lack of information on some of its analogs.
For the bisphenols, their metabolism has a protecting role. Their conjugation with glucuronic acid and sulfate is the main in vivo transformation for all of the bisphenols. In contrast to BPA as an agonist for the ERs, BPA glucuronide is without estrogenic activity [55]. Similar situations have been defined for the other bisphenol glucuronides, such as BPS glucuronide [56] and BPAF glucuronide [11]. A lack of estrogenic activity has also been shown for BPA sulfate [57]. In contrast to these conjugates, which are the main metabolites of the bisphenols, numerous oxidative metabolites of BPA have been detected. However, these were mainly reported for in vitro studies, whereas in vivo only hydroxylated BPA has been detected in feces in mice [58] and rats [59]. The estrogenic activity of the main BPA oxidative metabolite is lower than that of BPA [60]. Among the oxidative metabolites, two have shown significantly greater estrogenic activities than BPA: its ipso metabolite 4methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene (MBP) and hydroxycumyl alcohol. The MBP estrogenic activity has been determined in several in vitro and in vivo assays, in which it has shown up to 500-fold estrogenic activity over BPA ( Figure 5, Table 1) [16, [62][63][64][65]. Additionally, hydroxycumyl alcohol has shown 100-fold estrogenic activity over BPA [66]. However, there are questions about the in vivo relevance of these data. Indeed, although MBP has very high estrogenic activity, it has not been detected in vivo, as BPA glucuronidation is a much faster metabolic reaction in vivo. Hashimoto and coworkers evaluated the estrogenic activity of 13 BPA-related compounds using a yeast two-hybrid system without and with the addition of an S9 fraction [67]. Most of these chemicals showed enhanced estrogenic activities when the S9 fraction was added. This might be explained by the formation of oxidative metabolites with enhanced estrogenic activities [61]. A similar situation was reported for bisphenol B (BPB; 2,2-bis(4-hydroxyphenyl)butane), which is a more potent ER agonist than BPA [60]. Metabolism can also affect this BPB estrogenic activity. Here, after incubation of BPB with an S9 fraction, there was enhanced estrogenicity, which was probably due to the formation of BPB dimers [62,68]. Nevertheless, in vivo, glucuronidation is the predominant metabolic pathway for the bisphenols, while their oxidative metabolites are in most cases detected only in vitro.

Testing strategies
In vitro systems for evaluation of estrogenic activity are usually limited to target chemicals, without taking into account that many chemicals are extensively metabolized, which can have significant effects on their estrogenic activities. For some of the cell lines used for endocrine testing, metabolic activities have been confirmed. However, for reliable data, it is important that the metabolic capacity of any in vitro system is in good agreement with the in vivo conditions, although that can be difficult to ascertain. Bursztyka and coworkers [69] evaluated the metabolic capacities toward the known endocrine disruptors genistein and BPA for various cell lines that are commonly used in endocrine testing (i.e., the HepG2, MCF7, and HC11 cell lines) [69]. Phase I metabolic activities were not seen for these tested cell lines. The HepG2 and MCF7 cell lines showed glucuronidation and sulfation activities toward genistein and BPA, while the HC11 cell line was without metabolic activity. However, phase II metabolism in these cell lines was not representative of in vivo conditions. So, while sulfate conjugates of genistein and BPA were the main metabolites detected in these cell lines, it is known that genistein and BPA are mainly metabolized to glucuronide conjugates in vivo [69].
Testing strategies that include metabolic aspects have not been well defined. While different approaches can be used, they generally have many drawbacks. Jacobsen et al. [70] used two approaches: a compound-by-compound approach and an effects-based approach (Figure 6) [70]. Table 1. Estrogenic agonistic activity of MBP compared to BPA, according to various in vitro and in vivo assays [61].
In the compound-by-compound approach, the relevant metabolites are identified, isolated or synthesized, and then evaluated for their endocrine activities, together with the parent chemical. Moreover, mixtures of a parent chemical and its metabolites can be tested, to determine the effects of such mixtures (e.g., synergism, additive, and antagonistic). This approach is commonly used [16,56,63,71]. A drawback to this approach is that there is a need to conduct metabolic studies, as in many cases the metabolites are not known. Additionally, in vitro studies of metabolism can result in a "pallet" of metabolites, where not all will be relevant in vivo [61].
In the effects approach, the endocrine activity of the parent chemical is compared to the endocrine activity of the parent chemical treated with a metabolizing system, which is usually an S9 fraction [70]. Incorporation of such metabolic systems into in vitro assays is a common practice when testing for genotoxicity, like for the Ames test, where the S9 fraction is added as a source of metabolic enzymes, although such metabolic systems are still rarely used for the evaluation of endocrine activities of different chemicals [72].
In a recent study, a rat S9 fraction was incorporated in a CALUX reporter gene assay (i.e., the U2-OS cell line), and 27 chemicals were evaluated [73]. Selective inclusion of cofactors enables the evaluation of the different phases of metabolism on the estrogenic activities (i.e., phase I, nicotinamide adenine dinucleotide phosphate [reduced]; phases I and II, nicotinamide adenine dinucleotide phosphate [reduced], UDP-glucuronic acid, phosphoadenosylphosphosulfate, glutathione). These data showed that the endocrine activities for 23 of the 27 chemicals tested Figure 6. Testing strategies that include metabolic aspects. The compound-by-compound approach (a) and the effects approach (b), as proposed by Jacobsen and coworkers [70].
were affected by metabolism. Phase II metabolism resulted in decreased estrogenic activities, which is expected and is in agreement with in vivo data. For example, BPA and genistein showed lower estrogenic activities after phase II metabolism. In contrast, after phase I metabolism, 5 of the chemicals showed lower estrogenic activities, and 11 of the chemicals showed higher estrogenic activities [73].
However, also the effects approach has many weaknesses, as, for example, the metabolites formed in vitro are not necessarily formed in vivo. These data should therefore be interpreted with caution. The optimal path might therefore be the inclusion of both strategies (i.e., chemical by chemical, effects approach) [70]. Moreover, Jacobsen and coworkers proposed a five-step scheme for the evaluation of the endocrine effects of chemicals and their metabolites [70]: 1. The endocrine activity of the parent chemical should be determined. Then, based on all of the available information, an in vitro metabolizing system for the production of the metabolites should be selected (e.g., S9 fractions, microsomes, as the most common systems).
2. The compatibility of the metabolizing system and the test system for determination of the endocrine activities should then be evaluated.
3. The mixture of metabolites formed with the metabolizing system should then be evaluated for endocrine activity.
4.The influence of the metabolite mixture on the endocrine activity of the parent chemical should then be evaluated.
5. The endocrine activities of the pure metabolites and their mixtures should then be evaluated.

Conclusions
Metabolism is considered as a detoxification system that lowers biological activities and facilitates excretion of foreign chemicals. This appears to be true for many estrogenic chemicals, including E2, which is metabolized to numerous metabolites that have significantly lower estrogenic activities. However, some chemicals that are without estrogenic activity can be metabolized to potent estrogens. Some metabolic pathways in particular, such as hydroxylation on the para position of the aromatic ring, are dangerous in terms of the metabolic activation of proestrogens. Metabolic aspects should therefore be considered when testing chemicals for estrogenic activities.